{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:09:02Z","timestamp":1779797342442,"version":"3.53.1"},"reference-count":17,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Pregabalin, an antiepileptic drug with anxiolytic and analgesic properties, has been increasingly misused for recreational purposes. This article aimed to assess the extent and patterns of pregabalin misuse in India from a global perspective using pharmacovigilance data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective post-market observational study was conducted using VigiBase reports on pregabalin-related adverse drug reactions between January 2011 to April 2024. Data extraction and analysis were performed between April to May 2024. Relevant reports were identified using MedDRA term and analysed at global and Indian levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 40,582,030 adverse drug reactions (ADRs) in VigiBase, 163,476 involved pregabalins globally. Of these, 8,058 pregabalin abuse-related reports were identified, mainly intentional product misuse (n=3,560; 44.17%), intentional product use issue (n=2,203; 27.34%), and drug abuse (n=1,701; 21.11%). Globally, the USA reported the higher number of pregabalins ADRs, (n=96,867; 59.2%), followed by the Republic of Korea 9.4%, Japan 3.8% and France 3.6%. In India, 50 pregabalin-abuse reports were identified; of which drug abuse (n=26, 52%), intentional overdose (n=13, 26%), intentional product misuse (n=13, 26%), intentional product use-issue (n=4, 8%) and substance use disorder (n=1, 2%) were reported in patients within 18-44 yr (n=36, 72%) and predominantly in males (n=45, 90%). About 94% of reports were deemed serious, with 54% (n=27) requiring prolonged hospitalisation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation and conclusions<\/jats:title>\n                    <jats:p>Pregabalin misuse in India is prevalent, especially among adult men, and is often associated with serious outcomes. These findings emphasise the urgent need for stricter regulation and targeted interventions to limit misuse and reduce associated risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.25259\/ijmr_2462_2025","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T12:14:27Z","timestamp":1779020067000},"page":"649-654","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patterns of pregabalin misuse: Need for intervention"],"prefix":"10.25259","volume":"163","author":[{"given":"Tanushree","family":"Sarvepalli","sequence":"first","affiliation":[{"name":"Department of Pharmacovigilance Programme of India, #Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government of India, Ghaziabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Mewada","sequence":"additional","affiliation":[{"name":"Department of Materiovigilance Programme of India, #Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government of India, Ghaziabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shatrunajay","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Materiovigilance Programme of India, #Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government of India, Ghaziabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanandan","family":"Kalaiselvan","sequence":"additional","affiliation":[{"name":"Department of Pharmacovigilance Programme of India, #Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government of India, Ghaziabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"10.25259\/IJMR_2462_2025\/ref-1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2147\/IJGM.S405616","article-title":"Rise of pregabalin poisoning and abuse cases in Serbia: a ten-year retrospective study","volume":"16","author":"Antunovic","year":"2023","journal-title":"Int J Gen Med."},{"key":"10.25259\/IJMR_2462_2025\/ref-2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40263-024-01064-5","article-title":"Trends in pregabalin use and prescribing patterns in the adult population: a 10-year pharmacoepidemiologic study","volume":"38","author":"Benassayag Kaduri","year":"2024","journal-title":"CNS Drugs."},{"key":"10.25259\/IJMR_2462_2025\/ref-4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.pharma.2022.11.005","article-title":"D\u00e9tournement de la pr\u00e9gabaline \u00e0 des fins toxicomaniaques - \u00e9tat de la situation, risques et moyens de lutte [Drug abuse of pregabalin - state of the situation, risks and means of control]","volume":"81","author":"Laribi","year":"2023","journal-title":"Ann Pharm Fr."},{"key":"10.25259\/IJMR_2462_2025\/ref-5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and misuse of pregabalin and gabapentin: A systematic review update","volume":"81","author":"Evoy","year":"2021","journal-title":"Drugs."},{"key":"10.25259\/IJMR_2462_2025\/ref-8","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1111\/bcp.14276","article-title":"Patterns of pregabalin initiation and discontinuation after its subsidy in Australia","volume":"86","author":"Chiu","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"10.25259\/IJMR_2462_2025\/ref-9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/09687637.2020.1799943","article-title":"Online availability of gabapentin and pregabalin and the impact of legal reclassification in the United Kingdom","volume":"30","author":"Hockenhull","year":"2023","journal-title":"Drugs: Education, Prev Policy."},{"key":"10.25259\/IJMR_2462_2025\/ref-11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_283_23","article-title":"Very high dose of pregabalin abuse: A case report","volume":"65","author":"Gupta","year":"2023","journal-title":"Indian J Psychiatry."},{"key":"10.25259\/IJMR_2462_2025\/ref-12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-015-0303-6","article-title":"Abuse potential of pregabalin: A systematic review","volume":"30","author":"Schjerning","year":"2016","journal-title":"CNS Drugs."},{"key":"10.25259\/IJMR_2462_2025\/ref-13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: Basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Information J."},{"key":"10.25259\/IJMR_2462_2025\/ref-14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.24953\/turkjped.2020.30","article-title":"Pregabalin abuse in adolescence: A case series","volume":"64","author":"Alan","year":"2022","journal-title":"Turk J Pediatr."},{"key":"10.25259\/IJMR_2462_2025\/ref-15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5530\/ptb.2021.7.2","article-title":"Analysis of gabapentinoids abuse-reports in the middle east and North Africa region utilizing the food and drug administration adverse event reporting system","volume":"7","author":"Alsheikh","year":"2021","journal-title":"PTB Reports."},{"key":"10.25259\/IJMR_2462_2025\/ref-16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5694\/mja2.12036","article-title":"Pregabalin misuse-related ambulance attendances in Victoria, 2012\u20132017: Characteristics of patients and attendances","volume":"210","author":"Crossin","year":"2019","journal-title":"Med J Aust."},{"key":"10.25259\/IJMR_2462_2025\/ref-17","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3390\/healthcare9101281","article-title":"Community pharmacists\u2019 perceptions towards the misuse and abuse of pregabalin: A cross-sectional study from aseer region, Saudi Arabia","volume":"9","author":"Alshahrani","year":"2021","journal-title":"Healthcare (Basel)."},{"key":"10.25259\/IJMR_2462_2025\/ref-19","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s00228-010-0853-y","article-title":"A signal for an abuse liability for pregabalin\u2014results from the Swedish spontaneous adverse drug reaction reporting system","volume":"66","author":"Schwan","year":"2010","journal-title":"Eur J Clin Pharmacol."},{"key":"10.25259\/IJMR_2462_2025\/ref-20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jtumed.2021.04.009","article-title":"Abuse liability of gabapentin in the Saudi population after the pregabalin restriction: A cross-sectional study","volume":"16","author":"Alkhalaf","year":"2021","journal-title":"J Taibah Univ Med Sci."},{"key":"10.25259\/IJMR_2462_2025\/ref-21","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00228-013-1578-5","article-title":"Pregabalin abuse among opiate addicted patients","volume":"69","author":"Grosshans","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"10.25259\/IJMR_2462_2025\/ref-22","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3389\/fpsyt.2019.01022","article-title":"Pregabalin abuse in combination with other drugs: Monitoring among methadone patients","volume":"10","author":"Lancia","year":"2020","journal-title":"Front Psychiatry."}],"container-title":["The Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/patterns-of-pregabalin-misuse-need-for-intervention\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/patterns-of-pregabalin-misuse-need-for-intervention\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:54:12Z","timestamp":1779796452000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/patterns-of-pregabalin-misuse-need-for-intervention\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":17,"alternative-id":["10.25259\/IJMR_2462_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_2462_2025","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"article-number":"649"}}